2013
Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer.
Senzer N, LoRusso P, Martin L, Schilder R, Amaravadi R, Papadopoulos K, Segota Z, Weng D, Graham M, Adjei A. Phase II clinical activity and tolerability of the SMAC-mimetic birinapant (TL32711) plus irinotecan in irinotecan-relapsed/refractory metastatic colorectal cancer. Journal Of Clinical Oncology 2013, 31: 3621-3621. DOI: 10.1200/jco.2013.31.15_suppl.3621.Peer-Reviewed Original ResearchMedian progression-free survivalProgression-free survivalClinical activityRefractory/BP riskOverall clinical benefit rateRefractory metastatic colorectal cancerKRAS-MTBest supportive careClinical benefit rateMetastatic colorectal cancerReversible side effectsPhase 1 studySMAC mimetic birinapantAnti-tumor synergyPrior regimensSupportive careClinical benefitColorectal cancerKRAS WTOngoing treatmentSmac mimeticsBenefit rateMedian numberTherapeutic synergy
2012
Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens.
Fetterly G, Liu B, Senzer N, Amaravadi R, Schilder R, Martin L, LoRusso P, Papadopoulos K, Adjei A, Zagst P, McKinlay M, Weng D, Graham M. Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. Journal Of Clinical Oncology 2012, 30: 3029-3029. DOI: 10.1200/jco.2012.30.15_suppl.3029.Peer-Reviewed Original ResearchPaclitaxel/carboplatinMultiple chemotherapy regimensChemotherapy regimensWeekly dosingInterpatient variabilityLiposomal doxorubicinPK modelDose-proportional kineticsModerate interpatient variabilityPopulation PK modelPopulation PK modelingSMAC mimetic birinapantBlockade of apoptosisAdvanced malignanciesCombination regimensConcomitant administration